Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/6/2026

MMR Vaccine and Pregnancy Avoidance

  • Women should avoid pregnancy for 3 months after receiving the MMR vaccine or other rubella-containing vaccines, as recommended by the Centers for Disease Control and Prevention 1, 2, 3
  • Women should avoid pregnancy for 30 days after receiving monovalent measles or mumps vaccines, according to the Centers for Disease Control and Prevention 1, 2
  • The most recent guidance (2011) recommends avoiding pregnancy for 28 days after receipt of rubella-containing vaccine, as stated by the Centers for Disease Control and Prevention 4, 5

Rationale for Pregnancy Avoidance

  • The recommendation is based on theoretical concerns about potential risk to the fetus from live virus vaccines, as noted by the Centers for Disease Control and Prevention 1, 2
  • Although the risk is theoretical, it cannot be completely excluded, which is why pregnancy avoidance is recommended, according to the Centers for Disease Control and Prevention 6, 3
  • The rubella component of the vaccine is the primary concern driving the longer waiting period, as stated by the Centers for Disease Control and Prevention 7, 1

Safety Data if Pregnancy Occurs

  • If a woman becomes pregnant within 3 months after MMR vaccination, she should be counseled about the theoretical basis of concern, but this is not ordinarily a reason to consider pregnancy termination, as recommended by the Centers for Disease Control and Prevention 1, 2
  • No cases of congenital rubella syndrome or abnormalities attributable to vaccine virus infection have been observed in infants born to susceptible mothers who received MMR during pregnancy, according to the Centers for Disease Control and Prevention 1, 2
  • Long-term follow-up of 321 rubella-susceptible women who were vaccinated within 3 months before or after conception showed that none of the 324 infants had malformations compatible with congenital rubella syndrome, as reported by the Centers for Disease Control and Prevention 1, 2
  • The estimated risk for serious malformations attributable to RA 27/3 rubella vaccine ranges from zero to 1.6%, as estimated by the Centers for Disease Control and Prevention 4, 5

Clinical Practice Recommendations

  • Healthcare providers should ask women if they are pregnant before administering MMR and not vaccinate women who state they are pregnant, as recommended by the Centers for Disease Control and Prevention 1, 2
  • Healthcare providers should explain the potential theoretical risk to women who state they are not pregnant and counsel women who are vaccinated to avoid pregnancy for 3 months, according to the Centers for Disease Control and Prevention 1, 2, 7, 6
  • For postpartum women, non-immune women should receive MMR vaccine before discharge from the hospital or birthing center, although this recommendation is from Praxis Medical Insights, a similar recommendation is made by the Centers for Disease Control and Prevention to vaccinate non-immune women 1, 2
  • Breastfeeding is not a contraindication to MMR vaccination, as stated by the Centers for Disease Control and Prevention 1, 2

Special Considerations

  • Women who are not vaccinated because they are pregnant should be counseled about the risk of congenital rubella syndrome and the importance of vaccination after pregnancy, as recommended by the Centers for Disease Control and Prevention 1, 2

CDC Recommendations and Safety Evidence for Pre‑conception MMR Vaccination

Guideline Recommendations

  • The CDC (MMWR Recommendations and Reports, 1996) advised a 3‑month waiting period after receipt of the combined measles‑mumps‑rubella (MMR) vaccine before attempting conception. This precaution was based on theoretical risk considerations rather than documented adverse outcomes. 8, 9, 10

Counseling for Pregnancy after MMR Vaccination

  • If a woman becomes pregnant within 28 days of MMR vaccination, clinicians should explain that the risk of fetal harm is theoretical and extremely low, and that this circumstance alone does not constitute a reason to consider termination of pregnancy. Counseling should be based on available surveillance data showing no excess of congenital anomalies. 9, 10

Component‑specific Safety Evidence

  • Measles component: Current CDC surveillance provides no evidence that the measles virus in the MMR vaccine can infect the fetus or cause fetal abnormalities. 9, 10

  • Mumps component: Although the vaccine‑derived mumps virus can reach the placenta, there is no evidence that it leads to congenital malformations in humans. This conclusion is drawn from CDC‑reported post‑marketing surveillance. 8, 11

MMR Vaccine Contraindication and Management in Pregnancy

1. Contraindication Overview

  • The CDC (MMWR Recommendations and Reports) states that the measles‑mumps‑rubella (MMR) vaccine, which contains live attenuated viruses, is absolutely contraindicated during pregnancy because of theoretical risk of fetal infection, although actual documented harm is extraordinarily rare. 12
  • The contraindication is based on theoretical concerns that live virus could cross the placenta; no solid evidence of congenital malformations from the vaccine has been observed. 12
  • Although the mumps component can infect the placenta and fetus in animal studies, no human evidence links it to congenital malformations. 12

2. Inadvertent Vaccination During Pregnancy

  • If a pregnant woman receives MMR unintentionally, the CDC advises reassurance that pregnancy termination is not indicated solely because of the vaccination. 13

3. Safety Data from Inadvertent Exposure

Study Population Timing of Vaccination Outcome Measured Result
321 rubella‑susceptible pregnant women Vaccinated ≤ 3 months before conception Infants with malformations compatible with congenital rubella syndrome 0 cases reported
  • The observed risk of serious malformations after the RA 27/3 rubella vaccine strain is estimated at 0 %–1.6 %, which is markedly lower than the ≥ 20 % risk associated with natural rubella infection in the first trimester. (CDC) 13

4. Pre‑Vaccination Screening and Counseling (Women of Child‑Bearing Age)

  • The CDC recommends asking all women of child‑bearing potential whether they are pregnant or might become pregnant before administering MMR. Pregnant respondents should be excluded from vaccination. 12
  • Women should be counseled about the theoretical fetal risk and instructed to avoid pregnancy for at least 3 months after receiving MMR. 12

5. Post‑partum Vaccination and Breastfeeding

  • The CDC advises that non‑immune postpartum women receive MMR before hospital discharge, regardless of breastfeeding status. 13
  • Breastfeeding is not a contraindication; although rubella vaccine virus can be excreted in breast milk, transmission to the infant remains asymptomatic. 13

6. General Clinical Recommendations

  • Do not postpone MMR vaccination for minor febrile illnesses or require a routine physical examination when the woman appears healthy. (CDC) 13
  • Birth defects occurring after inadvertent vaccination should not be presumed causal; background prevalence of congenital anomalies is 3 %–5 % in all births, independent of vaccination status. (CDC) 13

REFERENCES